Cargando…
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
BACKGROUND: STK11 mutation (STK11(m)) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11(m) in stage III NSCLC pts treated with concurrent chemoradiation (CCRT) wit...
Autores principales: | An, Josiah, Yan, Melissa, Yu, Nanmeng, Chennamadhavuni, Adithya, Furqan, Muhammad, Mott, Sarah L., Loeffler, Bradley T., Kruser, Timothy, Sita, Timothy L., Feldman, Lawrence, Nguyen, Ryan, Pasquinelli, Mary, Hanna, Nasser H., Abu Hejleh, Taher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435393/ https://www.ncbi.nlm.nih.gov/pubmed/34584860 http://dx.doi.org/10.21037/tlcr-21-177 |
Ejemplares similares
-
Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report
por: Jonsdottir, Gudbjorg, et al.
Publicado: (2023) -
Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
por: An, Josiah, et al.
Publicado: (2022) -
Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target
por: Safi, Danish, et al.
Publicado: (2021) -
The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration
por: Zhang, Chenyue
Publicado: (2021) -
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)